Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Quantitative neuroiMaging In early Neurodegenerative Disease

Obiettivo

Neurodegenerative diseases, including Alzheimer’s disease (AD), pose a major global health and economic challenge, with over 10 million new cases annually and costs exceeding $1.3 trillion. As the first AD-modifying therapies emerge, their effectiveness depends on identifying the right patients at the appropriate stage. However, current diagnostic and clinical trial-support tools, such as PET scans and lumbar punctures, are costly, poorly scalable and have safety risks. This impairs patient stratification and trial efficiency, and delays diagnosis until significant neuronal loss has occurred, limiting treatment impact.

We are developing a quantitative toolkit to enable early detection of AD-related brain changes, before irreversible clinical symptoms develop, allowing timely interventions that prevent disease progression. Our platform transforms routine, widely accessible Magnetic Resonance Imaging (MRI) scans into personalised, population-referenced markers of brain health, building on over a decade of research in advanced brain MRI analytics. Using AI-driven normative models, our approach supports better patient stratification, including selection of individuals likely to respond to therapy, thus improving clinical trial outcomes, and enable early diagnosis.

Within this proof-of-concept, we will: i) consolidate MRI-derived markers of early AD, building upon our pilot evidence, ii) benchmark them against PET and evaluate their predictive power for progressive AD phenotypes, iii) independently validate their performance through industry & clinical partners, iv) devise a commercialisation plan through planned market research. Utilising existing industry links, we will initially focus on enhancing patient selection for AD clinical trials, building the evidence base for regulatory approval and clinical translation. Ultimately, our toolset will be productised to allow emerging clinical care pathways to be optimised, improving patient outcomes and healthcare economics.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

THE UNIVERSITY OF NOTTINGHAM
Contributo netto dell'UE
€ 150 000,00
Indirizzo
University Park
NG7 2RD Nottingham
Regno Unito
Regione
East Midlands (England) Derbyshire and Nottinghamshire Nottingham
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)